Bromosporine (Highly Pure)

<strong>Bromosporine (Highly Pure)</strong>_x000D_ <strong>Catalog number:</strong> B2019067_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 404.4 Da_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> −20°C_x000D_ <strong>Keywords:</strong> ethyl (3-methyl-6-(4-methyl-3-(methylsulfonamido)phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)carbamate_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Cheng X, Huang Z, Long D, Jin W. BET inhibitor bromosporine enhances 5-FU effect in colorectal cancer cells Biochem Biophys Res Commun. 2020 Jan 22;521(4):840-845._x000D_ 2: Pan H, Lu P, Shen Y, Wang Y, Jiang Z, Yang X, Zhong Y, Yang H, Khan IU, Zhou M, Li B, Zhang Z, Xu J, Lu H, Zhu H. The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells Oncotarget. 2017 Oct 6;8(55):94104-94116._x000D_ 3: Cen Y, Chen Y, Li X, Chen X, Yu B, Yan M, Yan N, Cheng H, Li S. Optical controlled and nuclear targeted CECR2 competitor to downregulate CSF-1 for metastatic breast cancer immunotherapy Biomaterials. 2024 Jul;308:122568._x000D_ 4: Dar AA, Bezrookove V, Nosrati M, Ice R, Patino JM, Vaquero EM, Parrett B, Leong SP, Kim KB, Debs RJ, Soroceanu L, Miller JR 3rd, Desprez PY, Cleaver JE, Salomonis N, McAllister S, Kashani-Sabet M. Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2206824119._x000D_ 5: Picaud S, Leonards K, Lambert JP, Dovey O, Wells C, Fedorov O, Monteiro O, Fujisawa T, Wang CY, Lingard H, Tallant C, Nikbin N, Guetzoyan L, Ingham R, Ley SV, Brennan P, Muller S, Samsonova A, Gingras AC, Schwaller J, Vassiliou G, Knapp S, Filippakopoulos P. Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia Sci Adv. 2016 Oct 12;2(10):e1600760._x000D_ 6: Roberts TC, Etxaniz U, Dall'Agnese A, Wu SY, Chiang CM, Brennan PE, Wood MJA, Puri PL. BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis Sci Rep. 2017 Jul 21;7(1):6153._x000D_ 7: Khan I, Kashani-Sabet M. Bromodomain inhibition targeting BPTF in the treatment of melanoma and other solid tumors Clin Exp Metastasis. 2024 Aug;41(4):509-515._x000D_ 8: Ngo V, Fleischmann BK, Jung M, Hein L, Lother A. Histone Deacetylase 6 Inhibitor JS28 Prevents Pathological Gene Expression in Cardiac Myocytes J Am Heart Assoc. 2022 Jun 21;11(12):e025857._x000D_ 9: Suh JL, Watts B, Stuckey JI, Norris-Drouin JL, Cholensky SH, Dickson BM, An Y, Mathea S, Salah E, Knapp S, Khan A, Adams AT, Strahl BD, Sagum CA, Bedford MT, James LI, Kireev DB, Frye SV. Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1 Biochemistry. 2018 Apr 10;57(14):2140-2149._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/31653342">10: Kato Y, Kondo S, Itakura T, Tokunaga M, Hatayama S, Katayama K, Sugimoto Y. SNAIL- and SLUG-induced side population phenotype of HCT116 human colorectal cancer cells and its regulation by BET inhibitors Biochem Biophys Res Commun. 2020 Jan 1;521(1):152-157. </a>_x000D_ _x000D_ <strong>Products Related to Bromosporine (Highly Pure) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>